Page 32 - ITPS-6-1

26 INNOSC Theranostics and Pharmacological Sciences, 2023, Vol. 6, No. 1 Kivrak, et al.

in scleroderma patients. The study provides an Vonk, M.C.; Walker, U.A.; Chung, L.; Collier, D.H.; Csuka, M.E.;
overview of cardiovascular disease risk factors in Fessler, B.J.; Guiducci, S.; Herrick, A.; Hsu, V.M.; Jimenez, S.;
Kahaleh, B.; Merkel, P.A.; Sierakowski, S.; Silver, R.M.;
scleroderma patients in the Turkish population. Our Simms, R.W.; Varga, J.; Pope, J.E. 2013 Classification Criteria
study is a pioneer for more complex studies to be for Systemic Sclerosis: An American College of Rheumatology/
European League Against Rheumatism Collaborative İnitiative.
done in the scleroderma patient group. Ann. Rheum. Dis., 2013, 72, 1747–55.
[5] Semenov, V.; Kuryata, O.; Lysunets, T. Clinical Pattern of
Acknowledgments Systemic Sclerosis in Central Ukraine. Association Between
Clinical Manifestations of Systemic Sclerosis and Hypertension.
None. [6] Reumatologia, 2018, 56(1), 24–30.
Minier, T.; Guiducci, S.; Bellando-Randone, S.; Bruni, C.; Lepri, G.;
Czirják, L.; Distler, O.; Walker, U.A.; Fransen, J.; Allanore, Y.;
Funding Denton, C.; Cutolo, M.; Tyndall, A.; Müller-Ladner, U.; Matucci-
Cerinic, M.; EUSTAR Co-Workers.; EUSTAR Co-Workers.
None. Preliminary Analysis of the Very Early Diagnosis of Systemic
Sclerosis (VEDOSS) EUSTAR Multicentre Study: Evidence for
Conflict of interest Puffy Fingers as a Pivotal Sign for Suspicion of Systemic Sclerosis.
Ann. Rheum. Dis., 2014, 73, 2087–93.
[7] Kuryata, O.V.; Lysunets. T.K.; Semenov, V.V. Risk and Predictors
The authors declare no conflicts of interests. of Development of Arterial Hypertension in Patients with Systemic
Sclerosis. Arterial Hypertens., 2017, 53, 17–22.
Author contribution [8] Underwood, J.C.; Cross, S.S. Osteoarticular and Connective
Tissues. In: Hughes, D.E.; editor. General and Systematic Pathology.
5 ed. Churchill Livingstone, Edinburgh, 2009. p710–474.
th
Conceptualization: Suleyman Serdar Koca [9] Agca, R.; Heslinga, S.C.; Rollefstad, S.; Heslinga, M.;
Formal analysis: Mehdi Karasu McInnes, I.B.; Peters, M.J.L.; Kvien, T.K.; Dougados, M.;
Investigation: Mehdi Karasu, Ozkan Karaca Radner, H.; Atzeni, F.; Primdahl, J.; Södergren, A.; Jonsson, S.W.;
Writing – original draft: Tarik Kivrak van Rompay, J.; Zabalan, C.; Pedersen, T.R.; Jacobsson, L.;
Writing – review & editing: Tarik Kivrak de Vlam, K.; Gonzalez-Gay, M.A.; Semb, A.G.; Kitas, G.D.;
Smulders, Y.M.; Szekanecz, Z.; Sattar, N.; Symmons, D.P.M.;
Nurmohamed, M.T. EULAR Recommendations for Cardiovascular
Disease Risk Management in Patients with Rheumatoid Arthritis
Ethics approval and consent to participate and Other Forms of İnflammatory Joint Disorders: 2015/2016
This study was approved by the Local Ethics Update. Ann. Rheum. Dis., 2017, 76, 17–28.
Committee (218714). [10] Argula, R.G.; Harley. R.A.; Silver, R.M. Is Systemic Sclerosis-
Related Pulmonary Arterial Hypertension a Distinct Phenotype? A
Lung Morphometric Analysis of Systemic Sclerosis-Associated vs.
Consent for publication İdiopathic Pulmonary Arterial Hypertension. J. Scleroderma Relat.
Disord., 2017, 2(suppl 1), s1–20.
Consent for publication was obtained from all the [11] Condliffe, R.; Howard, L.S. Connective tissue disease-associated
pulmonary arterial hypertension. F1000 Prime Cum, 2015, 7, 6.
participants. [12] Condliffe, R.; Kiely, D.G.; Peacock, A.J.; Corris, P.A.; Gibbs, J.S.;
Vrapi, F.; et al. Connective tissue disease-associated pulmonary
Availability of data arter- ial hypertension in the modern treatment era. Am. J. Respir.
Crit. Care Med., 2009, 179, 151–7.
The data can be obtained following request from [13] Al-Mutari, N. Skin Diseases Seen in Diabetes Mellitus. Bull.
Kuwait Inst. Med. Spec., 2006, 5, 30–9.
the corresponding author. [14] Pavlović, M.D.; Milenković, T.; Dinić, M.; Misović, M.;
Daković, D.; Todorović, S.; Daković, Z.; Zecevi, R.D.; Doder, R.
References The Prevalence of Cutaneous Manifestations in Young Patients
with Type 1 Diabetes. Diabetes Care, 2007, 30(8), 1964–7.
[15] Gruson, L.M.; Franks, A. Jr. Scleredema and Diabetic
Sclerodactyly. Dermatol. Online J., 2005, 11(4), 3.
[1] Nikpour, M.; Stevens, M.W.; Herrick, A.L.; Proudman, S.M. [16] Medsger, TA. Jr.; Masi, A.T.; Rodnan, G.P.; Benedek, T.G.;
Epidemiology of Systemic Sclerosis. Best Pract. Res. Clin. Robinson, H. Survival with Systemic Sclerosis (Scleroderma).
Rheumatol., 2010, 24, 857–69. A Life-Table Analysis of Clinical and Demographic Factors in 309
[2] Silman, A.J. Epidemiology of Scleroderma. Ann. Rheum. Dis., Patients. Ann. Intern. Med., 1971, 75(3), 369–76.
1991, 50, 846–53. [17] Boueiz, A.; Mathai, S.C.; Hummers, L.K.; Hassoun, P.M.
[3] Preliminary Criteria for the Classification of Systemic Sclerosis Cardiac Complications of Systemic Sclerosis: Recent Progress in
(Scleroderma). Subcommittee for Scleroderma Criteria of the Diagnosis. Curr. Opin. Rheumatol., 2010, 22(6), 696–703.
American Rheumatism Association Diagnostic and Therapeutic [18] Roman, M.J.; Salmon, J.E. Cardiovascular Manifestations of
Criteria Committee. Arthritis Rheum., 1980, 23, 581–90. Rheumatologic Diseases. Circulation, 2007, 116(20), 2346–55.
[4] Van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; [19] Denton, C.P.; Cables, J.B.; Phillips, G.D.; Wells, A.U.; Black, C.M.;
Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A. Jr.; Bois, R.M. Comparison of Doppler Echocardiography and Right
Carreira, P.E.; Riemekasten, G.; Clements, P.J.; Denton, C.P.; Heart Catheterization to Assess Pulmonary Hypertension in
Distler, O.; Allanore, Y.; Furst, D.E.; Gabrielli, A.; Mayes, M.D.; Systemic Sclerosis. Br. J. Rheumatol., 1997, 36(2), 239–43.
van Laar, J.M.; Seibold, J.R.; Czirjak, L.; Steen, V.D.; Inanc, M.; [20] Hachulla, E.; Gressin, V.; Guillevin, L.; Carpentier, P.; Diot, E.;
Kowal-Bielecka, O.; Müller-Ladner, U.; Valentini, G.; Veale, D.J.; Sibilia, J.; Kahan, A.; Cabane, J.; Francès, C.; Launay, D.;

©2023 AccScience Publishing